Standard Family Office LLC purchased a new stake in shares of Galapagos NV (NASDAQ:GLPG) during the 1st quarter, HoldingsChannel reports. The firm purchased 429 shares of the biotechnology company’s stock, valued at approximately $33,000.
A number of other institutional investors have also recently bought and sold shares of the business. Morgan Stanley grew its stake in Galapagos by 153.8% during the 4th quarter. Morgan Stanley now owns 127,657 shares of the biotechnology company’s stock valued at $12,636,000 after purchasing an additional 77,366 shares during the last quarter. OLD Mission Capital LLC boosted its stake in shares of Galapagos by 290.1% in the third quarter. OLD Mission Capital LLC now owns 113,719 shares of the biotechnology company’s stock worth $16,138,000 after buying an additional 84,569 shares during the last quarter. Voloridge Investment Management LLC boosted its stake in shares of Galapagos by 647.7% in the fourth quarter. Voloridge Investment Management LLC now owns 84,802 shares of the biotechnology company’s stock worth $8,394,000 after buying an additional 73,460 shares during the last quarter. Norges Bank purchased a new stake in shares of Galapagos in the fourth quarter worth about $6,929,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Galapagos by 17.0% in the fourth quarter. Wells Fargo & Company MN now owns 57,018 shares of the biotechnology company’s stock worth $5,643,000 after buying an additional 8,287 shares during the last quarter. Institutional investors and hedge funds own 10.05% of the company’s stock.
A number of analysts have recently commented on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Galapagos in a research note on Tuesday, May 11th. Citigroup downgraded Galapagos from a “buy” rating to a “neutral” rating in a research note on Thursday, February 11th. UBS Group restated a “neutral” rating on shares of Galapagos in a research note on Monday, April 12th. Raymond James upgraded Galapagos from a “market perform” rating to an “outperform” rating and set a $100.00 target price on the stock in a research note on Thursday, February 25th. Finally, Morgan Stanley upped their price target on Galapagos from $117.00 to $118.00 and gave the stock an “overweight” rating in a report on Monday, May 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $137.45.
Galapagos (NASDAQ:GLPG) last announced its earnings results on Thursday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $1.47. Galapagos had a negative return on equity of 10.05% and a negative net margin of 45.08%. The business had revenue of $137.29 million during the quarter, compared to analysts’ expectations of $104.06 million. On average, research analysts anticipate that Galapagos NV will post -5.28 earnings per share for the current fiscal year.
Galapagos Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis.
Featured Article: Options Trading – Understanding Strike Price
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.